Doug serves as a partner at DSW Ventures and brings extensive chief financial officer experience from roles at Videregen, SkinBioTherapeutics, and Cirrus.
Mira is an investment associate at DSW Ventures. She previously held research and laboratory roles at the Francis Crick Institute and the Institute of Cancer Research.
The Cranfield University spinout secured backing from DSW Ventures and Innovate UK to scale its engineering team and platform capabilities.
"We’re at the point where both advanced manufacturing and AI-native engineering need the same thing: faithful meshes from geometry that legacy tools simply can’t handle. ChopMesh is built natively for exactly that geometry, which uniquely positions us to serve both today’s aerospace and industrial engineers and the fast growing class of Phsyics-AI companies that depend on high-quality mesh data. This funding is a strong endorsement of that mission and the team behind it."
The Manchester-based startup has secured backing from DSW Ventures to further develop its AI agent platform.
"Nexco.ai has a compelling combination of a strong founding team, a well-defined market and a product that is already generating commercial interest. This makes Nexco.ai a truly exciting opportunity, and we’re thrilled to be backing the team at this early stage."
The oversubscribed round was led by DSW Ventures with backing from Scottish Enterprise, SWIM Capital and the University of Strathclyde.
"We’re excited to enter the next stage for Northern Light Microscopy. With the technology validated, this funding enables us to move forward into initial sales, scaling and product line expansion."
The fitness tech start-up raised the capital to support the hybrid sport boom.
"Hybrid fitness is the fastest-growing participation sport globally, yet the digital infrastructure supporting athletes has lagged behind. Our ambition is to build the technology layer that helps athletes train with greater precision, understand their performance and prepare effectively for competition."
The funding round was led by DSW Ventures with participation from XTX Ventures, Cambridge Technology Capital, angel investors, and Innovate UK.
"Our machine could pick up cancer, HIV or sepsis earlier – any disease with a nucleic acid trace. We’re made of DNA – that’s the source code. If you can pick up traces of faults and errors in that code, you can detect problems across the board before symptoms appear. We’ve built the ultimate needle-in-a-haystack detector – a tool that we can put in the hands of scientists to enable the discoveries of tomorrow."
